Gideon Capital Advisors Inc. Buys New Position in Jazz Pharmaceuticals PLC (JAZZ)

Gideon Capital Advisors Inc. bought a new position in shares of Jazz Pharmaceuticals PLC (NASDAQ:JAZZ) during the fourth quarter, Holdings Channel reports. The firm bought 2,543 shares of the specialty pharmaceutical company’s stock, valued at approximately $315,000.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in the company. Vanguard Group Inc. raised its stake in shares of Jazz Pharmaceuticals by 0.5% during the 3rd quarter. Vanguard Group Inc. now owns 4,882,984 shares of the specialty pharmaceutical company’s stock worth $820,975,000 after purchasing an additional 23,400 shares during the period. Vanguard Group Inc increased its holdings in Jazz Pharmaceuticals by 0.5% in the 3rd quarter. Vanguard Group Inc now owns 4,882,984 shares of the specialty pharmaceutical company’s stock worth $820,975,000 after acquiring an additional 23,400 shares during the last quarter. BlackRock Inc. increased its holdings in Jazz Pharmaceuticals by 2.7% in the 3rd quarter. BlackRock Inc. now owns 4,490,714 shares of the specialty pharmaceutical company’s stock worth $755,024,000 after acquiring an additional 118,634 shares during the last quarter. JPMorgan Chase & Co. increased its holdings in Jazz Pharmaceuticals by 3.0% in the 3rd quarter. JPMorgan Chase & Co. now owns 1,912,173 shares of the specialty pharmaceutical company’s stock worth $321,494,000 after acquiring an additional 56,291 shares during the last quarter. Finally, Bank of New York Mellon Corp increased its holdings in Jazz Pharmaceuticals by 14.0% in the 3rd quarter. Bank of New York Mellon Corp now owns 1,690,385 shares of the specialty pharmaceutical company’s stock worth $284,205,000 after acquiring an additional 207,954 shares during the last quarter. Institutional investors own 87.46% of the company’s stock.

A number of research analysts have weighed in on the company. BidaskClub raised Jazz Pharmaceuticals from a “hold” rating to a “buy” rating in a report on Monday, January 7th. Cantor Fitzgerald set a $185.00 target price on Jazz Pharmaceuticals and gave the company a “buy” rating in a report on Tuesday, February 26th. Morgan Stanley reduced their target price on Jazz Pharmaceuticals from $168.00 to $135.00 and set an “equal weight” rating for the company in a report on Friday, March 8th. Mizuho reduced their target price on Jazz Pharmaceuticals to $157.00 and set a “neutral” rating for the company in a report on Tuesday, November 20th. Finally, Wells Fargo & Co reissued a “buy” rating on shares of Jazz Pharmaceuticals in a report on Sunday, December 23rd. One research analyst has rated the stock with a sell rating, five have issued a hold rating and thirteen have assigned a buy rating to the company. The company currently has an average rating of “Buy” and a consensus price target of $188.56.



In related news, EVP Suzanne Sawochka Hooper sold 6,666 shares of the business’s stock in a transaction that occurred on Wednesday, February 27th. The stock was sold at an average price of $140.00, for a total value of $933,240.00. Following the completion of the sale, the executive vice president now owns 40,401 shares in the company, valued at approximately $5,656,140. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link. Also, SVP Paul Treacy sold 1,060 shares of the business’s stock in a transaction that occurred on Wednesday, March 6th. The stock was sold at an average price of $135.41, for a total value of $143,534.60. Following the completion of the sale, the senior vice president now owns 21,238 shares of the company’s stock, valued at approximately $2,875,837.58. The disclosure for this sale can be found here. Insiders sold a total of 11,668 shares of company stock valued at $1,606,567 in the last 90 days. 3.90% of the stock is currently owned by corporate insiders.

Shares of NASDAQ JAZZ opened at $134.80 on Friday. Jazz Pharmaceuticals PLC has a 12 month low of $113.52 and a 12 month high of $184.00. The company has a quick ratio of 3.42, a current ratio of 3.57 and a debt-to-equity ratio of 0.57. The stock has a market cap of $7.72 billion, a PE ratio of 11.01, a price-to-earnings-growth ratio of 0.89 and a beta of 1.23.

Jazz Pharmaceuticals (NASDAQ:JAZZ) last issued its quarterly earnings data on Tuesday, February 26th. The specialty pharmaceutical company reported $3.64 EPS for the quarter, topping the Thomson Reuters’ consensus estimate of $2.66 by $0.98. The company had revenue of $476.46 million during the quarter, compared to analyst estimates of $459.48 million. Jazz Pharmaceuticals had a return on equity of 26.20% and a net margin of 23.64%. Jazz Pharmaceuticals’s revenue was up 9.2% on a year-over-year basis. During the same quarter in the previous year, the firm earned $2.95 earnings per share. Sell-side analysts anticipate that Jazz Pharmaceuticals PLC will post 13.17 EPS for the current year.

TRADEMARK VIOLATION NOTICE: This piece of content was first posted by Dakota Financial News and is the sole property of of Dakota Financial News. If you are reading this piece of content on another domain, it was illegally stolen and reposted in violation of international copyright and trademark laws. The original version of this piece of content can be read at https://dakotafinancialnews.com/2019/03/15/gideon-capital-advisors-inc-buys-new-position-in-jazz-pharmaceuticals-plc-jazz.html.

Jazz Pharmaceuticals Company Profile

Jazz Pharmaceuticals plc, a biopharmaceutical company, identifies, develops, and commercializes pharmaceutical products for various medical needs in the United States, Europe, and internationally. The company has a portfolio of products and product candidates with a focus in the areas of sleep and hematology/oncology.

Recommended Story: Buy-Side Analysts

Want to see what other hedge funds are holding JAZZ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Jazz Pharmaceuticals PLC (NASDAQ:JAZZ).

Institutional Ownership by Quarter for Jazz Pharmaceuticals (NASDAQ:JAZZ)

Receive News & Ratings for Jazz Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Jazz Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.